Cagrilintide is a novel, investigational long-acting amylin analogue designed to regulate appetite and improve metabolic outcomes. Mimicking the natural hormone amylin, Cagrilintide enhances satiety, delays gastric emptying, and reduces food intake, contributing to clinically significant weight loss and improved glycemic control. It is often studied in combination with GLP-1 receptor agonists for synergistic effects on weight management and type 2 diabetes care. Cagrilintide offers promise with a mechanism complementary to existing incretin-based therapies.
Important Notice
This product is intended for research and laboratory use only. It is not approved for human or veterinary use, nor for diagnostic or therapeutic applications. Always handle with appropriate safety measures and comply with all relevant laws and regulations.